Principal Financial Group
ITOS

Principal Financial Group’s iTeos Therapeutics ITOS Stock Holding History

Principal Financial Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-16,430
Closed -$180K – 2462
2023
Q4 		$180K Sell
16,430
-135,912
-89% -$1.35M ﹤0.01% 2186
2023
Q3 		$1.67M Buy
152,342
+5,555
+4% +$71K ﹤0.01% 1789
2023
Q2 		$1.94M Sell
146,787
-8,370
-5% -$119K ﹤0.01% 1770
2023
Q1 		$2.11M Sell
155,157
-3,331
-2% -$59.7K ﹤0.01% 1752
2022
Q4 		$3.1M Sell
158,488
-10,661
-6% -$208K ﹤0.01% 1681
2022
Q3 		$3.22M Buy
169,149
+1,399
+0.8% +$32.2K ﹤0.01% 1628
2022
Q2 		$3.46M Buy
167,750
+31,004
+23% +$736K ﹤0.01% 1673
2022
Q1 		$4.4M Buy
+136,746
New +$4.97M ﹤0.01% 1702
2021
Q3 		– Sell
-8,090
Closed -$208K – 2599
2021
Q2 		$208K Buy
+8,090
New +$193K ﹤0.01% 2467

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Principal Financial Group's ITOS Position: Q1 2024 in Review

Principal Financial Group sold out of iTeos Therapeutics (ITOS) in Q1 2024, closing a stake of 16,430 shares — an estimated $180K sold.

Principal Financial Group first reported a position in ITOS in Q2 2021 and held it in 9 quarters. The position peaked at $4.4M in Q1 2022. 135 funds tracked by Wall St. Rank hold ITOS as of Q1 2024.

  • Principal Financial Group reported no remaining iTeos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Principal Financial Group sold 16,430 iTeos Therapeutics shares in Q1 2024, an estimated $180K.
  • Principal Financial Group first reported a position in iTeos Therapeutics in Q2 2021 and held it in 9 quarters.
  • Principal Financial Group's iTeos Therapeutics position peaked at $4.4M in Q1 2022.
  • 135 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q1 2024.

Based on Principal Financial Group's 13F filing for Q1 2024, filed 29 Apr 2024.